ArriVent BioPharma, Inc.
AVBP
$24.10
$1.225.33%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.17% | 7.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.96% | 25.59% | |||
| Operating Income | -13.96% | -25.59% | |||
| Income Before Tax | -10.68% | 51.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.68% | 51.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.68% | 51.23% | |||
| EBIT | -13.96% | -25.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 7.57% | 52.77% | |||
| Normalized Basic EPS | 6.96% | -24.69% | |||
| EPS Diluted | 7.57% | 52.77% | |||
| Normalized Diluted EPS | 6.96% | -24.69% | |||
| Average Basic Shares Outstanding | 19.73% | 3.27% | |||
| Average Diluted Shares Outstanding | 19.73% | 3.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||